The legendary Free Radical shooters live on thanks to determined fan developers, who are combining the original trilogy into ...
CervoMed to present 32-week results from its Phase 2b RewinD-LB study in dementia with Lewy bodies on July 28, 2025. CervoMed Inc. will host a conference call and webcast on July 28, 2025, at 8:00 AM ...
Based on the primary endpoint of Clinical Dementia Rating Sum of Boxes (CDR-SB), patients treated with neflamapimod showed 54% risk reduction in clinically significant worsening compared to control at ...
(RTTNews) - CervoMed Inc. (CRVO) is scheduled to present new results from the extension phase of its Phase 2b RewinD-LB study today. RewinD-LB was a phase IIb placebo-controlled trial, which assessed ...